# Nuclide record radioligand-therapy (technology). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/technologies/radioligand-therapy/>
  a schema:MedicalTherapy ;
  nuclide:kind "technology" ;
  schema:identifier "radioligand-therapy" ;
  schema:name "Radioligand therapy (beta emitters)"@en ;
  schema:description "A drug that finds tumour cells and carries a radioactive atom that irradiates them from inside the body."@en ;
  schema:url <https://nuclide.cc/technologies/radioligand-therapy/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Radioligand_therapy> ;
  schema:citation <https://en.wikipedia.org/wiki/Radioligand_therapy> ;
  nuclide:status "approved" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/technologies/spect/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/targets/sstr2/>, <https://nuclide.cc/targets/fap/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/lutathera/> ;
  nuclide:companies <https://nuclide.cc/companies/clarity-pharmaceuticals/>, <https://nuclide.cc/companies/abdera-therapeutics/>, <https://nuclide.cc/companies/alpha-9-oncology/>, <https://nuclide.cc/companies/ariceum-therapeutics/>, <https://nuclide.cc/companies/artbio/>, <https://nuclide.cc/companies/atomic-alchemy/>, <https://nuclide.cc/companies/evergreen-theragnostics/>, <https://nuclide.cc/companies/mariana-oncology/>, <https://nuclide.cc/companies/nucleus-radiopharma/>, <https://nuclide.cc/companies/point-biopharma/>, <https://nuclide.cc/companies/precirix/>, <https://nuclide.cc/companies/radionetics-oncology/>, <https://nuclide.cc/companies/ratio-therapeutics/> ;
  nuclide:journals <https://nuclide.cc/journals/cancer-biotherapy-and-radiopharmaceuticals/> ;
  nuclide:dependsOn <https://nuclide.cc/technologies/therapy-isotope-supply-chain/>, <https://nuclide.cc/technologies/radiopharmacy-network/>, <https://nuclide.cc/technologies/medical-cyclotrons-synthesis-modules/>, <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/technologies/radioligand-dosimetry/> .